The DOI matches its Crossref record; 446 of the 446 references it cites were found in a registry or an index.
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Abstract
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is one of the most frequently dysregulated signaling pathways observed in cancer patients that plays crucial roles in promoting tumor initiation, progression and therapy responses. This is largely due to that PI3K/Akt/mTOR signaling is indispensable for many cellular biological processes, including cell growth, metastasis, survival, metabolism, and others. As such, small molecule inhibitors targeting major kinase components of the PI3K/Akt/mTOR signaling pathway have drawn extensive attention and been developed and evaluated in preclinical models and clinical trials. Targeting a single kinase component within this signaling usually causes growth arrest rather than apoptosis associated with toxicity-induced adverse effects in patients. Combination therapies including PI3K/Akt/mTOR inhibitors show improved patient response and clinical outcome, albeit developed resistance has been reported. In this review, we focus on revealing the mechanisms leading to the hyperactivation of PI3K/Akt/mTOR signaling in cancer and summarizing efforts for developing PI3K/Akt/mTOR inhibitors as either mono-therapy or combination therapy in different cancer settings. We hope that this review will facilitate further understanding of the regulatory mechanisms governing dysregulation of PI3K/Akt/mTOR oncogenic signaling in cancer and provide insights into possible future directions for targeted therapeutic regimen for cancer treatment, by developing new agents, drug delivery systems, or combination regimen to target the PI3K/Akt/mTOR signaling pathway. This information will also provide effective patient stratification strategy to improve the patient response and clinical outcome for cancer patients with deregulated PI3K/Akt/mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–400 of 446
He, L., Wu, Y., Lin, L., Wang, J., Wu, Y., Chen, Y., Yi, Z., Liu, M., & Pang, X. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01778.x · Cited by 123
Matulonis, U. A., Vergote, I. B., Backes, F. J., Martin, L. P., McMeekin, S., Birrer, M. J., Campana, F., Xu, Y., Égile, C., & Ghamande, S. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.12.019 · Cited by 123
Akt2 expression correlates with prognosis of human hepatocellular carcinoma
Xu, X., Sakon, M., Nagano, H., Hiraoka, N., Yamamoto, H., Hayashi, N., Dono, K., Nakamori, S., Umeshita, K., Ito, Y., et al. (2004) · Oncology Reports · doi:10.3892/or.11.1.25 · Cited by 121
Phase II study of PX-866 in recurrent glioblastoma
Pitz, M. W., Eisenhauer, E. A., MacNeil, M. V., Thiessen, B. A., Easaw, J. C., Macdonald, D. R., Eisenstat, D. D., Kakumanu, A. S., Salim, M., Chalchal, H. I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou365 · Cited by 121
Wise-Draper, T. M., Moorthy, G., Salkeni, M. A., Karim, N. A., Thomas, H. E., Mercer, C. A., Beg, M. S., O’Gara, S., Olowokure, O. O., Fathallah, H., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0482-9 · Cited by 120
Idelalisib: First Global Approval
Markham, A. (2014) · Drugs · doi:10.1007/s40265-014-0285-6 · Cited by 119
Liu, Z., Zhu, G., Getzenberg, R. H., & Veltri, R. W. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25091 · Cited by 118
AKT Facilitates EGFR Trafficking and Degradation by Phosphorylating and Activating PIKfyve
Er, E. E., Mendoza, M. C., Mackey, A. M., Rameh, L. E., & Blenis, J. (2013) · Science Signaling · doi:10.1126/scisignal.2004015 · Cited by 116
Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0971 · Cited by 116
Tarantelli, C., Gaudio, E., Arribas, A. J., Kwee, I., Hillmann, P., Rinaldi, A., Cascione, L., Spriano, F., Bernasconi, E., Guidetti, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1041 · Cited by 116
Sirolimus effects on cancer incidence after kidney transplantation: a meta‐analysis
Yanik, E. L., Siddiqui, K., & Engels, E. A. (2015) · Cancer Medicine · doi:10.1002/cam4.487 · Cited by 115
Abdul‐Ghani, R., Serra, V., Győrffy, B., Jürchott, K., Solf, A., Dietel, M., & Schäfer, R. (2005) · Oncogene · doi:10.1038/sj.onc.1209201 · Cited by 115
McIntosh, E. M., Atkinson, T., Storms, R. K., & Smith, M. C. M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.329 · Cited by 115
Ho, D. W., Chan, L., Chiu, Y. T., Xu, M., Poon, R. T. P., Cheung, T. T., Tang, C. N., Tang, V. W., Lo, I. L., Lam, P. W. Y., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-312734 · Cited by 115
Song, L., Zhou, Z., Gan, Y., Li, P., Xu, Y., Zhang, Z., Luo, F., Xu, J., Zhou, Q., & Dai, F. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28244 · Cited by 115
Alcantara, D., Timms, A. E., Gripp, K. W., Baker, L., Park, K., Collins, S., Cheng, C. V., Stewart, F. A., Mehta, S. G., Saggar, A. K., et al. (2017) · Brain · doi:10.1093/brain/awx203 · Cited by 113
PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Wu, P., & Hu, Y.-Z. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710793361234 · Cited by 111
Ramírez-Moya, J., Wert-Lamas, L., & Santisteban, P. (2018) · Oncogene · doi:10.1038/s41388-017-0088-9 · Cited by 109
Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, J. R., & Park, B. H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9264-2 · Cited by 108
Heffron, T. P., Heald, R. A., Ndubaku, C. O., Wei, B. Q., Augistin, M., Do, S., Edgar, K. A., Eigenbrot, C. W., Friedman, L. S., Gancia, E., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01483 · Cited by 108
Chen, D., Lin, X., Zhang, C., Liu, Z., Chen, Z., Li, Z., Wang, J., Li, B., Hu, Y., Dong, B., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0132-2 · Cited by 107
Wen, P. Y., Cloughesy, T. F., Olivero, A. G., Morrissey, K. M., Wilson, T. R., Lu, X., Mueller, L. U., Coimbra, A. F., Ellingson, B. M., Gerstner, E. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2808 · Cited by 107
Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
Zhang, Y., Yan, H., Xu, Z., Yang, B., Luo, P., & He, Q. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1663169 · Cited by 105
Tachibana, M., Shibakita, M., Ohno, S., Kinugasa, S., Yoshimura, H., Ueda, S., Fujii, T., Rahman, M. A., Dhar, D. K., & Nagasue, N. (2002) · Cancer · doi:10.1002/cncr.0678 · Cited by 104
Juric, D., Bono, J. S. D., LoRusso, P. M., Nemunaitis, J. J., Heath, E. I., Kwak, E. L., Macarulla, T. M., Geuna, E., Miguel, M. J. D., Patel, C. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2888 · Cited by 103
Aïssat, N., Tourneau, C. L., Ghoul, A., Serova, M., Bièche, I., Lokiec, F. M., Raymond, É., & Faivre, S. J. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0609-2 · Cited by 102
Emerging Role of MicroRNAs in mTOR Signaling
Zhang, Y., Huang, B., Wang, H., Chang, A., & Zheng, X. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2485-1 · Cited by 102
Chen, S., Wu, J., Jiao, K., Wu, Q., Ma, J., Chen, D., Kang, J., Zhao, G., Shi, Y., Fan, D., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0950-x · Cited by 101
Ippen, F. M., Grosch, J. K., Subramanian, M. P., Kuter, B. M., Liederer, B. M., Plise, E. G., Mora, J. L., Nayyar, N., Schmidt, S., Giobbie‐Hurder, A., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz105 · Cited by 101
Androgen deprivation–induced NCoA2 promotes metastatic and castration-resistant prostate cancer
Qin, J., Lee, H.-J., Wu, S., Lin, S., Lanz, R. B., Creighton, C. J., DeMayo, F. J., Tsai, S. Y., & Tsai, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76412 · Cited by 100
Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant
Gkeka, P., Evangelidis, T., Pavlaki, M., Lazani, V., Christoforidis, S., Agianian, B., & Cournia, Z. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003895 · Cited by 100
Chakraborty, S., Mohiyuddin, S. M. A., Gopinath, K., & Kumar, A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-163 · Cited by 100
Mueller, S., Phillips, J. J., Onar‐Thomas, A., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos140 · Cited by 100
Papadopoulos, K. P., Tabernero, J. M., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J. M., Shi, W., Égile, C., Ruiz-Soto, R., Laird, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2403 · Cited by 99
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
Mithal, P., Allott, E. H., Gerber, L., Reid, J., Welbourn, W., Tikishvili, E., Park, J., Younus, A., Sangale, Z., Lanchbury, J. S. S., et al. (2014) · International Journal of Urology · doi:10.1111/iju.12571 · Cited by 98
LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control
Gan, W., Dai, X., Dai, X., Xie, J., Yin, S., Zhu, J., Wang, C., Liu, Y., Guo, J., Wang, M., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0463-6 · Cited by 98
Self-citationFujimoto, Y., Morita, T., Ohashi, A., Haeno, H., Hakozaki, Y., Fujii, M., Kashima, Y., Kobayashi, S. S., & Mukohara, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78646-y · Cited by 98
PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner
Tang, Y., & Eng, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1557 · Cited by 97
Rictor Forms a Complex with Cullin-1 to Promote SGK1 Ubiquitination and Destruction
Gao, D., Wan, L., Inuzuka, H., Berg, A. H., Tseng, A., Zhai, B., Shaik, S., Bennett, E. J., Tron, A. E., Gasser, J. A., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.016 · Cited by 96
Barlaam, B. C., Cosulich, S. C., Degorce, S. L., Fitzek, M., Green, S. A., Hancox, U. J., der Brempt, C. L., Lohmann, J.-J. M., Maudet, M., Morgentin, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501629p · Cited by 95
Smith, M. C., Mader, M. M., Cook, J. A., Iversen, P. W., Ajamie, R. T., Perkins, E. J., Bloem, L. J., Yip, Y. Y., Barda, D. A., Waid, P. P., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0996 · Cited by 95
Wen, P. Y., Omuro, A. M. P., Ahluwalia, M. S., Fathallah‐Shaykh, H. M., Mohile, N. A., Lager, J. J., Laird, A., Tang, J., Jiang, J., Égile, C., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov083 · Cited by 94
D'Amato, V., Rosa, R., D’Amato, C., Formisano, L., Marciano, R., Nappi, L., Raimondo, L., Mauro, C. D., Servetto, A., Fusciello, C., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.241 · Cited by 94
Hancox, U. J., Cosulich, S. C., Hanson, L. L., Trigwell, C. B., Lenaghan, C., Ellston, R. P. A., Dry, H., Crafter, C., Barlaam, B. C., Fitzek, M., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0406 · Cited by 93
Brandão, M., Caparica, R., Eiger, D., & de Azambuja, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz280 · Cited by 93
Kolinsky, M. P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.074 · Cited by 92
Cushing, T. D., Hao, X., Shin, Y., Andrews, K. L., Brown, M., Cardozo, M. G., Chen, Y., Duquette, J., Fisher, B., de Turiso, F. G.-L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501624r · Cited by 91
Rashmi, R., DeSelm, C. J., Helms, C., Bowcock, A. M., Rogers, B. E., Rader, J. S., Grigsby, P. W., & Schwarz, J. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092948 · Cited by 91
Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00776-6 · Cited by 90
Akt-Mediated Phosphorylation of XLF Impairs Non-Homologous End-Joining DNA Repair
Liu, P., Gan, W., Guo, C., Xie, A., Gao, D., Guo, J., Zhang, J., Willis, N. A., Su, A., Asara, J. M., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.01.005 · Cited by 90
Self-citationHuw, L.-Y., O'Brien, C. L., Pandita, A., Mohan, S., Spoerke, J. M., Lu, S., Wang, Y., Hampton, G. M., Wilson, T. R., & Lackner, M. R. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.46 · Cited by 90
The butterfly effect in cancer: A single base mutation can remodel the cell
Hart, J. R., Zhang, Y., Liao, L., Ueno, L. A., Du, L., Jonkers, M., Yates, J. R., & Vogt, P. K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424012112 · Cited by 89
Class I PI 3-kinases: Function and evolution
Kriplani, N., Hermida, M. A., Brown, E. R., & Leslie, N. R. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.05.002 · Cited by 88
Langer, C. J., Redman, M. W., Wade, J. L., Aggarwal, C., Bradley, J. D., Crawford, J., Stella, P. J., Knapp, M. H., Miao, J., Minichiello, K., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.029 · Cited by 88
Birt–Hogg–Dubé syndrome is a novel ciliopathy
Luijten, M., Basten, S. G., Claessens, T., Vernooij, M., Scott, C. L., Janssen, R., Easton, J. A., Kamps, M. A. F., Vreeburg, M., Broers, J. L. V., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt288 · Cited by 86
Espósito, A., Viale, G., & Curigliano, G. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0034 · Cited by 86
Hall, C. P., Reynolds, C. P., & Kang, M. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0114 · Cited by 85
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
Ghosh, A. P., Marshall, C. B., Coric, T., Shim, E., Kirkman, R. L., Ballestas, M. E., Ikura, M., Bjornsti, M., & Sudarshan, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4963 · Cited by 84
Graham, L. S., Banda, K., Torres, A., Carver, B. S., Chen, Y., Pisano, K., Shelkey, G., Curley, T., Scher, H. I., Lotan, T. L., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0578-9 · Cited by 84
Brandt, C., Hillmann, P., Noack, A., Römermann, K., Öhler, L. A., Rageot, D., Beaufils, F., Melone, A., Sele, A., Wymann, M. P., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.08.002 · Cited by 84
Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility
Jhanwar-Uniyal (2009) · International Journal of Oncology · doi:10.3892/ijo_00000386 · Cited by 83
Dickler, M. N., Saura, C., Richards, D., Krop, I. E., Cervantes, A. M. R., Bedard, P. L., Patel, M. R., Pusztai, L., Oliveira, M., Cardenas, A. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0613 · Cited by 83
Li, J., Davies, B., Han, S., Zhou, M., Bai, Y., Zhang, J., Xu, Y., Tang, L., Wang, H., Liu, Y.-J., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-241 · Cited by 82
Huynh, H. T., Hao, H.-X., Chan, S. L., Chen, D., Ong, R., Soo, K. C., Pochanard, P., Yang, D. T., Ruddy, D. A., Liu, M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0768 · Cited by 82
Locatelli, S. L., Careddu, G., Serio, S., Consonni, F. M., Maeda, A., Viswanadha, S., Vakkalanka, S. V. S., Castagna, L., Santoro, A., Allavena, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1133 · Cited by 82
PTEN arginine methylation by PRMT6 suppresses PI3K–AKT signaling and modulates pre-mRNA splicing
Feng, J., Dang, Y., Zhang, W., Zhao, X., Zhang, C., Hou, Z., Jin, Y., McNutt, M. A., Marks, A. R., & Yin, Y. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811028116 · Cited by 82
Gu, Y., Lin, S., Li, J., Nakagawa, H., Chen, Z., Jin, B., Tian, L., Uçar, D. A., Shen, H., Lu, J., et al. (2011) · Oncogene · doi:10.1038/onc.2011.247 · Cited by 81
Son, M. K., Ryu, Y.-L., Jung, K. H., Lee, H., Lee, H. S., YAN, H. H., Park, H. J., Ryu, J., Suh, J., Hong, S., et al. (2013) · Scientific Reports · doi:10.1038/srep03470 · Cited by 81
Targeting AKT/PKB to improve treatment outcomes for solid tumors
Iida, M., Harari, P. M., Wheeler, D. L., & Toulany, M. (2020) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2020.111690 · Cited by 81
Yap, T. A., Li, Y., Patnaik, A., Tunariu, N., Biondo, A., Fearen, I., Papadopoulos, K. P., Olmos, D., Baird, R. D., Delgado, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0868 · Cited by 80
Zhu, Q., Youn, H., Tang, J., Tawfik, O. W., Dennis, K. L., Terranova, P. F., Du, J., Raynal, P., Thrasher, J. B., & Li, B. (2008) · Oncogene · doi:10.1038/onc.2008.91 · Cited by 80
Liu, T., Sun, Q., Li, Q., Yang, H., Zhang, Y., Wang, R., Lin, X., Xiao, D., Yuan, Y., Chen, L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0548 · Cited by 80
Wang, H., Li, Q., Tang, S., Li, M., Feng, A., Qin, L., Liu, Z., & Wang, X. (2016) · Hematology · doi:10.1080/10245332.2016.1258152 · Cited by 79
García‐Escudero, R., Segrelles, C., Dueñas, M., Pombo, M. T., Ballestín, C., Alonso, M., Nenclares, P., Álvarez‐Rodríguez, R., Aniceto, G. S., Ruiz-Alonso, A., et al. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.02.014 · Cited by 79
Regulation of PTEN expression by noncoding RNAs
Li, W., Zhang, T., Guo, L., & Huang, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0898-9 · Cited by 78
Mutational Analysis of AKT1, AKT2 and AKT3 Genes in Common Human Carcinomas
Soung, Y. H., Lee, J. W., Nam, S. W., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2006) · Oncology · doi:10.1159/000096289 · Cited by 77
Roulin, D., Waselle, L., Dormond-Meuwly, A., Dufour, M., Demartines, N., & Dormond, O. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-90 · Cited by 77
Zumsteg, Z. S., Morse, N., Krigsfeld, G. S., Gupta, G. P., Higginson, D. S., Lee, N. Y., Morris, L. G. T., Ganly, I., Shiao, S. L., Powell, S. N., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2245 · Cited by 76
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors
McLeod, R., Kumar, R., Papadatos-Pastos, D., Mateo, J., Brown, J. S., Garces, A. I., Ruddle, R. R., Decordova, S., Jueliger, S., Ferraldeschi, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0700 · Cited by 76
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Thijssen, R., ter Burg, J., Garrick, B., van Bochove, G. G. W., Brown, J. R., Fernandes, S. M., Rodriguez, M. S., Michot, J., Hallek, M. J., Eichhorst, B. F., et al. (2016) · Blood · doi:10.1182/blood-2016-02-700328 · Cited by 75
Mortensen, D. S., Perrin-Ninkovic, S. M., Shevlin, G. I., Elsner, J., Zhao, J., Whitefield, B., Tehrani, L. R., Sapienza, J., Riggs, J. R., Parnes, J. S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00627 · Cited by 75
MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis
Wang, W., Li, J., Zhu, W. J., Gao, C., Jiang, R., Li, W., Hu, Q., & Zhang, B. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-819 · Cited by 74
Semba, S., Itoh, N., Ito, M., Youssef, E. M., Harada, M., Moriya, T., Kimura, W., & Yamakawa, M. (2002) · PubMed · Cited by 74
Jo, H., Lo, P., Li, Y., Loison, F., Green, S., Wang, J. X., Silberstein, L. E., Ye, K., Chen, H., & Luo, H. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019062108 · Cited by 73
Lin, H., Huang, Z., Liu, J., Qiu, Y., Tao, Y., Wang, M., Yao, H., Hou, K., Gu, F., & Xu, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-28519-2 · Cited by 73
Kim, S. T., Kim, S., Klempner, S. J., Yoon, J. Y., Kim, N., Ahn, S., Bang, H., Kim, K., Park, W., Park, S. H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw669 · Cited by 72
MiR-424/503-Mediated Rictor Upregulation Promotes Tumor Progression
Oneyama, C., Kito, Y., Asai, R., Ikeda, J., Yoshida, T., Okuzaki, D., Kokuda, R., Kakumoto, K., Takayama, K., Inoue, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080300 · Cited by 71
Lamhamedi-Cherradi, S.-E., Menegaz, B. A., Ramamoorthy, V., Vishwamitra, D., Wang, Y., Maywald, R. L., Buford, A. S., Fokt, I., Skóra, S., Wang, J., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw182 · Cited by 71
Du, L., Chen, X., Cao, Y. Q., Lu, L., Zhang, F.-C., Bornstein, S., Li, Y., Owens, P., Malkoski, S. P., Said, S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.1 · Cited by 70
Nakanishi, Y., Walter, K., Spoerke, J. M., O'Brien, C. L., Huw, L. Y., Hampton, G. M., & Lackner, M. R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2201 · Cited by 69
Musa, F., Alard, A., David‐West, G., Curtin, J. P., Blank, S. V., & Schneider, R. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0926 · Cited by 69
Oricchio, E., Katanayeva, N., Collier, M. D., Sungalee, S., Pasion, J. P., Béguelin, W., Battistello, E., Sanghvi, V. R., Jiang, M., Jiang, Y., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9969 · Cited by 69
Blagden, S. P., Hamilton, A. L., Mileshkin, L., Wong, S., Michael, A., Hall, M., Goh, J. C. H., Lisyanskaya, A. S., DeSilvio, M., Frangou, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2277 · Cited by 69
WICKI, A. N., Brown, N. F., Xyrafas, A., Bize, V., Hawle, H., Berardi, S., Cmiljanović, N., Cmiljanović, V., Stumm, M., Dimitrijević, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.012 · Cited by 68
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002
Kunnimalaiyaan, M., Ndiaye, M. A., & Chen, H. (2006) · Surgery · doi:10.1016/j.surg.2006.06.040 · Cited by 67
Wang, X., Cao, X., Sun, R., Tang, C., Tzankov, A., Zhang, J., Manyam, G. C., Xiao, M., Miao, Y., Jabbar, K. J., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.03.002 · Cited by 67
Xie, M., Fu, Z., Cao, J., Liu, Y., Wu, J., Li, Q., & Chen, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.088 · Cited by 66
Sui, H. X., Pan, S.-F., Feng, Y., Jin, B.-H., Liu, X., Zhou, L., Hou, F., Wang, W., Fu, X., Han, Z., et al. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-279 · Cited by 65
Hassan, B., Akçakanat, A., Sangai, T., Evans, K. W., Adkins, F. C., Eterovic, A. K., Zhao, H., Chen, K., Chen, H., Do, K.-A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2337 · Cited by 65
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
Lim, S. M., Park, H. S., Kim, S., Kim, S., Ali, S. M., Greenbowe, J. R., Yang, I. S., Kwon, N., Lee, J., Ryu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7234 · Cited by 65
Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN–AKT axis
Coronel-Hernández, J., López–Urrutia, E., Contreras-Romero, C., Delgado-Waldo, I., Figueroa‐González, G., Campos-Parra, A. D., Salgado-García, R., Martínez-Gutiérrez, A. D., Rodríguez-Morales, M., Jacobo-Herrera, N. J., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0802-5 · Cited by 65
Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
Chen, Y., Huang, L., Dong, Y., Tao, C., Zhang, R., Shao, H., & Shen, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.573599 · Cited by 65
Chen, L., Jin, T., Zhu, K., Piao, Y., Quan, T., Quan, C., & Lin, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.14442 · Cited by 64
Zhou, B., Wei, C., Zhang, S., Zhang, Z., & Gao, H. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26502 · Cited by 64
Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells
Fujiwara, M., Izuishi, K., Sano, T., Hossain, M. A., Kimura, S., Masaki, T., & Suzuki, Y. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-76 · Cited by 63
Identification of recurrent fusion genes across multiple cancer types
Yu, Y., Liu, P., Nelson, J. B., Hamilton, R. L., Bhargava, R., Michalopoulos, G. K., Chen, Q., Zhang, J., Ma, D., Pennathur, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38550-6 · Cited by 63
Self-citationPaired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Park, S., Shim, J., Lee, B., Cho, I., Park, W., Kim, Y., Lee, S., Choi, Y., Han, J., Ahn, J. S., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.024 · Cited by 63
Breast tumors from CHEK2 1100delC- mutation carriers: genomic landscape and clinical implications
Muranen, T., Greco, D., Fagerholm, R., Kilpivaara, O., Kämpjärvi, K., Aittomäki, K., BLOMQVIST, C. P., Heikkilä, P., Borg, Å., & Nevanlinna, H. A. (2011) · Breast Cancer Research · doi:10.1186/bcr3015 · Cited by 62
Yamamoto, T., Kanaya, N., Somlo, G., & Chen, S. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05104-9 · Cited by 62
Tolcher, A. W., Kurzrock, R., Valero, V., Gonzalez, R. C., Heist, R. S., Tan, A. R., Means-Powell, J. A., Werner, T. L., Becerra, C. R., Wang, C., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04038-8 · Cited by 62
Wang, J., Lv, X., Guo, X., Dong, Y., Peng, P., Huang, F., Wang, P., Zhang, H. M., Zhou, J., Wang, Y., et al. (2021) · Oncogenesis · doi:10.1038/s41389-020-00292-w · Cited by 62
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma
Liu, J., Zhou, X.-K., Chen, J.-H., Yi, G., Chen, H.-G., Ba, M.-C., Lin, S.-Q., & Qi, Y.-C. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i39.4986 · Cited by 61
Coussy, F., Botty, R. E., Lavigne, M., Gu, C., Fuhrmann, L., Briaux, A., de Koning, L., Dahmani, A., Montaudon, É., Morisset, L., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-0846-y · Cited by 61
Tolaney, S. M., Burris, H. A., Gartner, E. M., Mayer, I. A., Saura, C., Maurer, M., Ciruelos, E., García, A. A., Campana, F., Wu, B., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3248-4 · Cited by 59
Yamaji, M., Ota, A., Wahiduzzaman, M., Karnan, S., Hyodo, T., Konishi, H., Tsuzuki, S., Hosokawa, Y., & Haniuda, M. (2017) · Cancer Medicine · doi:10.1002/cam4.1179 · Cited by 59
Cook, M. M., Rabadi, L. S. A., Kaempf, A. J., Saraceni, M. M., Savin, M. A., & Mitri, Z. I. (2020) · The Oncologist · doi:10.1002/onco.13609 · Cited by 59
Lauring, J. D., Cosgrove, D., Fontana, S. C., Gustin, J. P., Konishi, H., Abukhdeir, A. M., Garay, J. P., Mohseni, M., Wang, G., Higgins, M. J., et al. (2010) · Oncogene · doi:10.1038/onc.2009.516 · Cited by 58
Tzenaki, N., Andreou, M., Stratigi, K., Vergetaki, A., Makrigiannakis, A., Vanhaesebroeck, B., & Papakonstanti, E. A. (2012) · The FASEB Journal · doi:10.1096/fj.11-198192 · Cited by 58
Alaei-Mahabadi, B., Bhadury, J., Karlsson, J. W., Nilsson, J. A., & Larsson, E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606220113 · Cited by 58
Akagi (2009) · International Journal of Oncology · doi:10.3892/ijo_00000202 · Cited by 57
Zorea, J., Prasad, M., Cohen, L., Li, N., Schefzik, R., Ghosh, S., Rotblat, B., Brors, B., & Elkabets, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1025-8 · Cited by 56
Dey, N., Leyland-Jones, B. R., & De, P. K. (2015) · Europe PMC (PubMed Central) · Cited by 55
Tang, J. C. O. (2010) · Oncology Reports · doi:10.3892/or_00000832 · Cited by 55
R�os, S., Wright, A. J., D’Santos, P., Hu, D., Hesketh, R. L., Lubling, Y., Georgopoulou, D., Lerda, G., Couturier, D., Razavi, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.016 · Cited by 55
Milestones in the Use of Combined-Modality Radiation Therapy and Chemotherapy
Lawrence, T. S., Haffty, B. G., & Harris, J. R. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2281 · Cited by 54
Control of mTOR signaling by ubiquitin
Jiang, Y., Su, S., Zhang, Y., Qian, J., & Liu, P. (2019) · Oncogene · doi:10.1038/s41388-019-0713-x · Cited by 54
Self-citationZhang, X., Shen, L., Liu, Q., Hou, L., & Huang, L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.039 · Cited by 54
Lee, H., Jung, K. H., Jeong, Y., Hong, S., & Hong, S. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.020 · Cited by 53
Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex
Neklesa, T. K., & Davis, R. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807712105 · Cited by 53
Hayman, T. J., Wahba, A., Rath, B. H., Bae, H. R., Kramp, T. R., Shankavaram, U. T., Camphausen, K. A., & Tofilon, P. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2136 · Cited by 53
Langdon, S., Hughes, A. M., Taylor, M. A., Kuczynski, E. A., Mele, D. A., Delpuech, O., Jarvis, L., Staniszewska, A. D., Cosulich, S. C., Carnevalli, L. S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1458810 · Cited by 53
PTEN mutation spectrum in breast cancers and breast hyperplasia
Yang, J.-L., Ren, Y., Wang, L., Li, B., Chen, Y., Zhao, W., Xu, W., Li, T., & Dai, F. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0781-3 · Cited by 52
Levy, B. P., Spira, A. I., Becker, D. J., Evans, T. L., Schnadig, I. D., Camidge, D. R., Bauman, J. E., Hausman, D. F., Walker, L. N., Nemunaitis, J. J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000183 · Cited by 52
Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma
Calero, R., Morchon, E., Martínez‐Argudo, I., & Serrano, R. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.021 · Cited by 52
McKinnon, T., Venier, R. E., Yohe, M. E., Sindiri, S., Gryder, B. E., Shern, J. F., Kabaroff, L., Dickson, B. C., Schleicher, K., Chouinard-Pelletier, G., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0122-y · Cited by 52
MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2
Zheng, Y., Xiao, K., Xiao, G.-C., Tong, S., Ding, Y., Wang, Q., Li, S., & Hao, Z.-N. (2016) · Oncology Letters · doi:10.3892/ol.2016.4814 · Cited by 51
Koppenhafer, S. L., Goss, K. L., Terry, W. W., & Gordon, D. J. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0260 · Cited by 51
MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy
Mognato, M., & Celotti, L. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150709115355 · Cited by 50
miR‑221‑3p promotes the cell growth of non‑small cell lung cancer by targeting p27
Yin, G.-Q., Zhang, B., & Li, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10291 · Cited by 50
Janne, P. A., Cohen, R. B., Laird, A., Macé, S., Engelman, J. A., Ruiz-Soto, R., Rockich, K. T., Xu, J., Shapiro, G. I., Martínez, P., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000088 · Cited by 49
Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma
Patel, K., Danilov, A. V., & Pagel, J. M. (2019) · Blood · doi:10.1182/blood.2019001795 · Cited by 49
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Keam, B., Kim, S., Ahn, Y., Kim, T. M., Lee, S., Kim, D., & Heo, D. S. (2015) · PubMed · Cited by 48
Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)Preprint
Biesecker, L. G., Edwards, M. J., O’Donnell, S., Doherty, P., MacDougall, T., Tith, K., Kazakin, J., & Schwartz, B. E. (2020) · Molecular Case Studies · doi:10.1101/mcs.a004549 · Cited by 48
Kannan, K., Coarfa, C., Chao, P.-W., Luo, L., Wang, Y., Brinegar, A. E., Hawkins, S. M., Milosavljevic, A., Matzuk, M. M., & Yen, L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501735112 · Cited by 47
Yuzugullu, H., Baitsch, L., Von, T., Steiner, A., Tong, H., Ni, J., Clayton, L. K., Bronson, R., Roberts, T. M., Gritsman, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9501 · Cited by 47
Moench, R., Grimmig, T., Kannen, V., Tripathi, S., Faber, M., Moll, E.-M., Chandraker, A. K., Lissner, R., Germer, C., Waaga-Gasser, A. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11899 · Cited by 47
Gazi, M., Moharram, S. A., Marhäll, A., & Kazi, J. U. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.035 · Cited by 47
Makinoshima, H., Umemura, S., Suzuki, A., Nakanishi, H., Maruyama, A., Udagawa, H., Mimaki, S., Matsumoto, S., Niho, S., Ishii, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2109 · Cited by 47
PIK3CA gene aberrancy and role in targeted therapy of solid malignancies
Willis, O., Choucair, K., Alloghbi, A., Stanbery, L., Mowat, R. B., Brunicardi, F. C., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0164-0 · Cited by 46
Matissek, K. J., Onozato, M. L., Sun, S., Zheng, Z., Schultz, A., Lee, J., Patel, K., Jerevall, P.-L., Saladi, S. V., Macleay, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0535 · Cited by 45
Hong, D. S., Moore, K. N., Bendell, J. C., Karp, D. D., Wang, J. S.-Z., Ulahannan, S. V., Jones, S. F., Wu, W., Donoho, G. P., Ding, Y. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3242 · Cited by 45
Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency
Hasanovic, A., & Mus‐Veteau, I. (2018) · Cells · doi:10.3390/cells7080107 · Cited by 44
Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
Caro‐Vegas, C., Bailey, A., Bigi, R., Damania, B., & Dittmer, D. P. (2019) · mBio · doi:10.1128/mbio.02871-18 · Cited by 44
Barlaam, B. C., Cosulich, S. C., Delouvrié, B., Ellston, R. P. A., Fitzek, M., Germain, H., Green, S. A., Hancox, U. J., Harris, C. S., Hudson, K., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.002 · Cited by 43
Kulkarni, A. A., Natarajan, S. K., Chandrasekar, V., Pandey, P. R., & Sengupta, S. (2016) · ACS Nano · doi:10.1021/acsnano.6b01600 · Cited by 42
Daniel, P. M., Filiz, G., Brown, D. V., Christie, M., Waring, P., Zhang, Y., Haynes, J. M., Pouton, C. W., Flanagan, D. J., Vincan, E., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy068 · Cited by 42
Tolaney, S. M., Im, Y., Calvo, E., Lu, Y., Hamilton, E. P., Forero, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0645 · Cited by 42
Lin, J., Feng, J., Yang, H., Yan, Z., Li, Q., Wei, L., Lai, Z., Jin, Y., & Peng, J. (2017) · Oncology Reports · doi:10.3892/or.2017.5892 · Cited by 41
MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression
Jiang, Y., Zhang, Y., Leung, J. Y., Fan, C., Popov, K. I., Su, S., Qian, J., Wang, X., Holtzhausen, A., Ubil, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09233-7 · Cited by 41
Self-citationLi, F., Li, Z., Han, Q., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1227-2 · Cited by 41
Kostaras, E., Kaserer, T., Lazaro, G., Heuss, S. F., Hussain, A., Casado, P., Hayes, A., Yandım, C., Palaskas, N. J., Yu, Y., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0889-4 · Cited by 41
Bernard, M., Cardin, G. B., Cahuzac, M., Ayad, T., Bissada, É., Guertin, L., Bahig, H., Nguyen‐Tan, P. F., Filion, É., Ballivy, O., et al. (2020) · Cancers · doi:10.3390/cancers12092371 · Cited by 41
The Roles of Post-Translational Modifications on mTOR Signaling
Yin, S., Liu, L., & Gan, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041784 · Cited by 41
Zhou, J., Toh, S. H. M., Chan, Z.-L., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0581-9 · Cited by 40
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
Fricke, S. L., Payne, S. N., Favreau, P. F., Kratz, J. D., Pasch, C. A., Foley, T. M., Yueh, A. E., Hey, D. R. V. D., Depke, M. G., Korkos, D. P., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0510 · Cited by 40
Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts
Shugg, R. P. P., Thomson, A., Tanabe, N., Kashishian, A., Steiner, B. H., Puri, K. D., Pereverzev, A., Lannutti, B. J., Jirik, F. R., Dixon, S. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.507525 · Cited by 39
da Costa, A. A. B. A., Costa, F. D., Ribeiro, A. R., Guimarães, A. P., Chinen, L. T. D., Lopes, C. A. P., & de Lima, V. C. C. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0707-1 · Cited by 38
The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression
Choucair, K., Guérard, K., Ejdelman, J., Chevalier, S., Yoshimoto, M., Scarlata, E., Fazli, L., Sircar, K., Squire, J. A., Brimo, F., et al. (2012) · Translational Oncology · doi:10.1593/tlo.12286 · Cited by 38
Activating AKT2 Mutation: Hypoinsulinemic Hypoketotic Hypoglycemia
Arya, V. B., Flanagan, S. E., Schober, E., Rami-Merhar, B. M., Ellard, S., & Hussain, K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3228 · Cited by 38
Doi, T., Fuse, N., Yoshino, T., Kojima, T., Bando, H., Miyamoto, H., Kaneko, M., Osada, M., & Ohtsu, A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3198-0 · Cited by 38
Wu, N., Zhu, Y., Xu, X., Zhu, Y., Song, Y., Pang, L., & Chen, Z. (2018) · Journal of Cancer · doi:10.7150/jca.22861 · Cited by 38
Kim, H. R., Kang, H. N., Yun, M. R., Ju, K. Y., Choi, J. W., Jung, D. M., Pyo, K., Hong, M. H., Ahn, M.-J., Sun, J., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01074-2 · Cited by 38
Lattanzio, L., Tonissi, F., Monteverde, M., Vivenza, D., Russi, E. G., Milano, G. A., Merlano, M. C., & Nigro, C. L. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0210-1 · Cited by 37
Zaidi, A. H., Kosovec, J. E., Matsui, D., Omstead, A. N., Raj, M. S., Rao, R. R., Biederman, R. W., Finley, G. G., Landreneau, R. J., Kelly, R. J., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001908 · Cited by 37
Bedard, P. L., Davies, M. A., Kopetz, S., Juric, D., Shapiro, G. I., Luke, J. J., Spreafico, A., Wu, B., Castell, C., Gomez, C., et al. (2017) · Cancer · doi:10.1002/cncr.31044 · Cited by 37
Abdallah, M. E., El-Readi, M. Z., Althubiti, M., Almaimani, R. A., Ismail, A. M., Idris, S., Refaat, B., Almalki, W. H., Babakr, A. T., Mukhtar, M. H., et al. (2020) · Molecules · doi:10.3390/molecules25153355 · Cited by 37
Tan, E. S., Cao, B., Kim, J., Al‐Toubah, T., Mehta, R. J., Centeno, B. A., & Kim, R. D. (2020) · Cancer · doi:10.1002/cncr.33364 · Cited by 37
Nada, S., Mori, S., Takahashi, Y., & Okada, M. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-397925-4.00015-8 · Cited by 36
Xu, P., Yang, J., Liu, J., Yang, X., Liao, J., Yuan, F., Liu, B., & Chen, Q. (2018) · Oncology Reports · doi:10.3892/or.2018.6845 · Cited by 36
Kim, M.-Y., Kruger, A. J., Jeong, J.-Y., et al. (2019) · Molecules and Cells · doi:10.14348/molcells.2019.2395 · Cited by 36
Lesma, E. A., Sirchia, S. M., Ancona, S., Carelli, S., Bòsari, S., Ghelma, F., Montanari, E., Giulio, A. M. D., & Gorio, A. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080799 · Cited by 35
Qian, X.-J., Li, Y.-T., Yu, Y., Yang, F., Deng, R., Ji, J., Jiao, L., Li, X., Wu, R.-Y., Chen, W.-D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3016 · Cited by 34
Mortensen, D. S., Perrin-Ninkovic, S. M., Harris, R., Lee, B. G. S., Shevlin, G. I., Hickman, M., Khambatta, G., Bissonette, R., Fultz, K. E., & Sankar, S. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.035 · Cited by 34
Christensen, T. D., Palshof, J. A., Larsen, F. O., Poulsen, T. S., Høgdall, E. V. S., Pfeiffer, P., Jensen, B. V., Yilmaz, M., & Nielsen, D. L. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1433322 · Cited by 34
Alternative polyadenylation confers PtenmRNAs stability and resistance to microRNAs
Thivierge, C., Tseng, H.-W., Mayya, V. K., Lussier, C. R., Gravel, S., & Duchaîne, T. F. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky666 · Cited by 34
Chen, K., Shang, Z., Dai, A.-L., & Dai, P.-L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117816 · Cited by 34
Discovery of Novel Anticancer Therapeutics Targeting the Pi3K/Akt/Mtor Pathway
Maira, S.-M., Furet, P., & Stauffer, F. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.5 · Cited by 33
Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer
Solomon, B., & Pearson, R. B. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a74dba · Cited by 33
Dumont, F. J., Staruch, M. J., Grammer, T. C., Blenis, J., Kastner, C. A., & Rupprecht, K. M. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1100 · Cited by 33
Basu, B., Krebs, M., Sundar, R., Wilson, R. H., Spicer, J. F., Jones, R., Brada, M., Talbot, D. C., Steele, N. L., Garces, A. I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy245 · Cited by 33
Papadopoulos, K. P., Égile, C., Ruiz‐Soto, R., Jiang, J., Shi, W., Bentzien, F., Rasco, D., Abrisqueta, P., Vose, J. M., & Tabernero, J. M. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.974040 · Cited by 32
Li, A., Zhang, R., Zhang, Y., Liu, X., Wang, R., Liu, J., Liu, X., Xie, Y., Cao, W., Xu, R., et al. (2019) · PubMed · Cited by 32
Huang, T., Brill, E., Nair, J. R., Zhang, X., Wilson, K. M., Chen, L., Thomas, C. J., & Lee, J. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1439 · Cited by 32
Targeting Akt by SC66 triggers GSK-3β mediated apoptosis in colon cancer therapy
Liu, Y., Huang, Y., Ding, J., Liu, N., Peng, S., Wang, J., Wang, F., & Zhang, Y. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0837-7 · Cited by 31
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
Fujishita, T., Kojima, Y., Kajino‐Sakamoto, R., Taketo, M. M., & Aoki, M. (2017) · Oncogene · doi:10.1038/onc.2017.242 · Cited by 30
Wolin, E. M., Mita, A. C., Mahipal, A., Meyer, T., Bendell, J. C., Nemunaitis, J. J., Münster, P. N., Paz-Ares, L. G., Filvaroff, E. H., Li, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221994 · Cited by 30
Nanotechnology-Based Targeting of mTOR Signaling in Cancer
Yoon, M. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s254574 · Cited by 30
Isoform-Selective PI3K Inhibitors for Various Diseases
Bheemanaboina, R. R. Y. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200106141717 · Cited by 29
Jeong, J.-Y., Kim, K.-S., Moon, J.-S., Song, J.-A., Choi, S.-H., Kim, K.-I., Kim, T.-H., & An, H. (2013) · Apoptosis · doi:10.1007/s10495-013-0807-9 · Cited by 28
Pradella, L. M., Lang, M., Kurelac, I., Mariani, E., Guerra, F., Zuntini, R., Tallini, G., Mackay, A. G., Reis-Filho, J. S., Seri, M., et al. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.8 · Cited by 28
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Advances in the role of STAT3 in macrophage polarization
Xia, T., Zhang, M., Lei, W., Yang, R., Fu, S., Fan, Z., Yang, Y., & Zhang, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160719 · Cited by 284
Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression
Xue, C., Li, G., Lu, J., & Li, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00788-w · Cited by 268
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Chen, G., Zhang, H., Sun, H., Ding, X., Liu, G., Yang, F., Feng, G., Dong, X., Zhu, Y., Wang, X., et al. (2023) · Apoptosis · doi:10.1007/s10495-023-01855-z · Cited by 47
Metadata
- Authors
- Yu, L., Wei, J., & Liu, P.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 85
- Pages
- 69-94
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W3176165488
- Cited by
- 763
- References
- 446
- FWCI
- 23.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.